Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
Business Wire•11/11/2026•16:05 ET
0
Key Highlights
- ➤ZUNVEYL Q3 net product revenue $7.8M, up approximately 30% sequentially
- ➤Q3 bottles dispensed 10,896, up approximately 31% quarter-over-quarter
- ➤Cumulative prescribers reached 2,410, exceeding the 2026 goal early
- ➤Operating loss improved to approximately $6.4M despite $13.7M expenses
- ➤Cash totaled approximately $37.8M with no debt at September 30
Expert Statements
Michael McFadden, Chief Executive Officer of Alpha Cognition
“The third quarter was our strongest quarter since the launch of ZUNVEYL, the first new oral Alzheimer’s treatment approved in more than 15 years”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“We delivered strong demand growth and record prescriber and facility adoption while maintaining disciplined operating spending. We exceeded our original full-year prescriber goal a quarter early while increasing the productivity of our commercial organization. We believe this combination of sustained growth, improving commercial efficiency and spending discipline supports our goal of operating profitability in 2027.”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“We are continuing to build real-world evidence in the setting where these patients are actually treated. Our CONVERGE results speak directly to the potential for ZUNVEYL to make a difference. We believe that the growing body of real-world evidence, together with improving payer access, positions ZUNVEYL well for continued growth.”
Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update
ZUNVEYL® net product revenue increased approximately 30% quarter-over-quarter to $7.8 million in the third quarter of 2026, driven by continued prescription growth; revenue increased more than 230% year-over-year.
Get started
Create a free account to read the full story.